Clinical trials: latest news

Clinical trials features

Clinical trials in your own words

Clinical trials news from aidsmap

More news

Clinical trials news selected from other sources

  • Should everyone be getting the HIV prevention pill as part of this HIV vaccine study?

    More than 500 people have signed up since December to be part of the country’s largest HIV vaccine trial, but some experts are crying foul over what they say is unequal access to the HIV prevention pill among participants.

    30 June 2017 | Bhekisisa
  • Slow start to landmark South African HIV vaccine trial

    Stringent global standards to enlist participants are slowing the process of volunteering to participate in South Africa’s ground-breaking HIV vaccine trial, known as HVTN 702.

    02 June 2017 | Medical Brief
  • We had to run our own trial for TB drugs – nobody else was doing it

    Four years ago, Médecins Sans Frontières (MSF) made the decision to sponsor and run its own tuberculosis clinical trial. The aim was to find a new treatment regimen for drug-resistant tuberculosis (TB) that was radically better than what was currently available. As an organisation that specialises in delivering short-term emergency healthcare, this was a bold and new direction to take. But it was a decision that came from our frustration, anger and impatience on behalf of the more than 20,000 people with TB that we treat every year. We felt compelled to search for improved treatments ourselves because too few pharmaceutical companies, organisations or universities were doing enough about it.

    02 June 2017 | The Guardian
  • Three countries get first malaria vaccine

    The world's first vaccine against malaria will be introduced in three countries - Ghana, Kenya and Malawi - starting in 2018. The four-shot vaccine should prevent four in 10 cases of the disease.

    24 April 2017 | BBC
  • The New War on Drugs: Trump policy on the FDA

    A war against regulations intended to hold manufacturers accountable, protect drug safety and the health of the American public, and advance evidence-based and cost-effective care is questionable at best—and dangerous at worst.

    01 April 2017 | TAG
  • Mariëtte Botes: ARV pioneer who became the victim of abuse and hostility

    Dr Mariëtte Botes, who has died in Pretoria at the age of 50, was an early pioneer of antiretroviral cocktails that saved the lives of hundreds of thousands of people with Aids. But, reports The Times, while running a clinical trial at Kalafong Hospital in Pretoria in 1999, she became the target of a hostile campaign by Patricia de Lille, who was then an MP for the PAC, who accused her of abusing and exploiting her patients.

    16 March 2017 | Medical Brief
  • What we know about the new England PrEP trial

    @teamPrEPster, and other HIV advocate groups, will be keeping a watchful eye on development of the trial, not least to ensure that there are no further delays to its implementation.

    27 February 2017 | Prepster
  • How to Keep HIV Cure-Related Trials Ethical: The Benefit/Risk Ratio Challenge

    While high or unknown risks are a mainstay of early-phase trials in areas like cancer research, cure study participants typically have a safe and efficacious alternative to those risks: remaining on antiretrovirals. Can we justify asking patients who are doing well on antiretrovirals to accept the risk and uncertainty of many HIV cure-related trials? If we cannot, we might need to give up on the hope of curing HIV, or of achieving controlled remission.

    22 February 2017 | BMJ Blogs
  • Vaccine trial: Community trust is key

    Dr. Linda-Gail Bekker knows from more than 20 years in the field that researchers have to work hand in hand with the communities most affected if they want to halt an epidemic. And the townships are ground zero for HIV/AIDS in Cape Town.

    17 February 2017 | Fred Hutch
  • Pharma industry shuns Trump push for radical shift at FDA

    President Donald Trump's vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines.

    15 February 2017 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.